Evidence map›Paper›PMID 42726575›Full record

ReviewNanomaterials (Basel, Switzerland)2026

Advances and Prospects of Chiral Plasmonic Nanomaterials in Emerging Applications.

Panangattukara Prabhakaran Praveen Kumar

Abstract readReview
In one paragraph

Review in Nanomaterials (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Panangattukara Prabhakaran Praveen KumarDepartment of Biomedical Engineering, Institute for Quantitative Health Science and Engineering, Michigan State University, East Lansing, MI 48824, USA.ORCID 0000-0002-9189-0074

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chiral plasmonic nanostructures have emerged as a distinctive class of optical materials that combine nanoscale structural asymmetry with strong light-matter interactions, enabling pronounced and tunable chiroptical responses. Advances in structural engineering and plasmonic coupling have enabled diverse architectures with potential applications in enantioselective sensing, asymmetric catalysis, bioimaging, and therapeutic technologies. However, their broader development remains constrained by several key challenges, including precise control over nanoscale chirality, batch-to-batch structural reproducibility, incomplete understanding of structure-chiroptical property relationships, scalable fabrication, and stability under practical and biological conditions. This review systematically examines the major structural architectures of chiral plasmonic nanomaterials and the mechanisms responsible for chirality generation, including ligand-induced, intrinsic geometric, and assembly induced chirality. Particular emphasis is placed on correlating structural design, plasmonic coupling, and chiroptical properties with functional performance. Recent advances in enantioselective recognition and sensing, catalytic transformations, and biomedical applications are critically discussed, together with their current limitations. Finally, emerging design strategies and future opportunities for improving structural precision, reproducibility, scalability, and practical translation are highlighted, providing a framework for the rational development of next-generation chiral plasmonic nanomaterials.

Indexed as

bioimagingbiosensingchiralitychiral nanoparticlesenantioselective detectiontherapy

Identifiers

PMID42726575
PMCPMC13567732

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.